425 related articles for article (PubMed ID: 19952863)
1. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
[TBL] [Abstract][Full Text] [Related]
2. Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
5. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
6. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
7. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
[TBL] [Abstract][Full Text] [Related]
8. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
9. [Safety of the bivalent human papillomavirus vaccine--results following administration of more than 192,000 doses].
van der Maas NA; Kemmeren JM; de Melker HE
Ned Tijdschr Geneeskd; 2009; 153():A964. PubMed ID: 19930738
[TBL] [Abstract][Full Text] [Related]
10. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
11. Introducing human papillomavirus vaccines - questions remain.
Paavonen J; Lehtinen M
Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
13. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
[TBL] [Abstract][Full Text] [Related]
14. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
[TBL] [Abstract][Full Text] [Related]
15. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.
Chang S; O'Connor PM; Slade BA; Woo EJ
Vaccine; 2013 Feb; 31(10):1447-52. PubMed ID: 23142308
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
17. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM; Pitlick JM; Forinash AB
Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
[TBL] [Abstract][Full Text] [Related]
18. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.
Bonanni P; Cohet C; Kjaer SK; Latham NB; Lambert PH; Reisinger K; Haupt RM
Vaccine; 2010 Jul; 28(30):4719-30. PubMed ID: 20451636
[TBL] [Abstract][Full Text] [Related]
19. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.
Hildesheim A; Markowitz L; Avila MH; Franceschi S
Vaccine; 2006 Aug; 24 Suppl 3():S3/227-32. PubMed ID: 16950011
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System.
Borja-Hart NL; Benavides S; Christensen C
Ann Pharmacother; 2009 Feb; 43(2):356-9. PubMed ID: 19155346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
